Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese male healthy subjects aged from 18 to 55 years (including the boundary value)；~* BMI between 18-28kg/m2 (including boundary value) and body weight between 55-85kg;~* Normal physical examination results or abnormal with no clinical significance according to the doctor's judgment;~* The subject (including partner) has no pregnancy plan or sperm donation plan during the whole trial period and within 6 months after the completion of the study, and voluntarily adopts effective contraceptive measures;~* Sign the informed consent before joining the study, and fully understand the content, process and possible risks;~* Willing and able to comply with the visits and treatments of the trial protocol.~Exclusion Criteria:~* Clinical laboratory examination results are abnormal and with clinical significance, or other clinical findings indicate diseases with clinical significance within one year prior to screening;~* ECG is abnormal and has clinical significance (judged by the investigator);~* With active infection within two months before screening, including acute and chronic infection and local infection;~* Hepatitis B and/or Hepatitis C; or HIV antigen/antibody positive; or Treponema pallidum antibody positive;~* Having taken any prescription drug, over-the-counter drug, any vitamin product or herbal medicine within 28 days before screening (or within 5 half-lives of the above drugs, whichever is longer);~* Having participated in drug clinical trials within 3 months before the study administration, or planning to participate in other drug clinical trials during the study period;~* Acute disease occurred or with concomitant medication from the screening to use of the study drug; major injury or surgery or fracture occurred within 4 weeks before enrollment, or surgery was planned during the study;~* Having used ustekinumab, anti-tumor necrosis factor (TNF) or interleukin (IL) targeting agents, or having used any biological products or monoclonal antibodies within 3 months before screening;~* Any immunoglobulin biologicals were used one year prior to screening;~* Having received within 12 weeks prior to initiating treatment or planning to receive live virus or live vaccines during the study;~* Suspected or confirmed as allergic constitution (allergic to variety of drugs or food), or allergic to ustekinumab, or severe allergic or allergic reaction to monoclonal antibody;~* Blood donation or massive blood loss (\> 450 ml) within 3 months before using the study drug, or planning to donate blood during the study, or having received blood transfusion within 8 weeks before screening;~* Employees or relatives of all investigators, clinical centers, clinical research organizations or sponsors cannot be included in the group;~* Subjects considered unsuitable by the investigators.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BAT2206 injection (Type: EXPERIMENTAL): 45mg; subcutaneous injection
- Stelara(US-licensed) (Type: ACTIVE_COMPARATOR): 45mg; subcutaneous injection
- Stelara(EU-licensed) (Type: ACTIVE_COMPARATOR): 45mg; subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete